US-based clinical-stage biopharmaceutical company Dragonfly Therapeutics, Inc announced on Monday that it has named Dr Susan Altschuller as its new chief financial officer.

Dr Altschuller, a seasoned senior biopharma executive, has over two decades of strategic and financial leadership experience at pharmaceutical and biotechnology companies. She has served as the chief financial officer of Cerevel Therapeutics, chief financial officer of ImmunoGen, vice president and head of investor relations and later, head of enterprise finance at Alexion. Dr Altschuller has also worked as head of investor relations at Bioverativ and served in various positions in Biogen finance and as senior consultant at the Frankel Group.

Bill Haney, Dragonfly Therapeutics co-founder and CEO, said, 'We are delighted that Susan has joined Dragonfly. Her leadership growing successful biopharma companies comes at an exciting time as Dragonfly expands our clinical pipeline in autoimmune disease, oncology, and neuro-inflammatory disease. Susan's powerful combination of financial, clinical and development experience will help drive our mission to help patients by inventing and commercialising leading immune-engaging therapeutics.'